This study was designed to evaluate the implantation of internal cardioverter/defibrillators under local anaesthesia by electrophysiologists and to compare this to our former experience of implants with general anaesthesia.
Introduction
In recent years, the technique of implanting internal cardioverter/defibrillators had undergone rapid change. Initially conceptualized as a transvenous device by Mirowski et alP\ subsequently epicardial placement of defibrillating electrodes by thoracotomy became a standard implantation technique 12 " 11 . Endocardial leads were later reintroduced in combination with subcutaneous patch electrodes' biphasic shock application) has made implants in the left subpectoral region possible. Single lead systems are now available' 81 in which the device itself serves as a defibnllation electrode with a relatively large area ('active can'). Usually the implantation of internal cardioverter/ defibrillators is carried out under general anaesthesia.
This study aims to compare outcome following implantation under local and under general anaesthesia using the improved and facilitated pectoral implant operation technique made possible by smaller devices.
Patients and methods

Patient characteristics
Forty-seven patients underwent cardioverter/ defibrillator implantation. All but one patient had a history of ventricular tachycardia or aborted sudden cardiac death (see Table 1 for details). In 33 patients coronary artery disease, in 13 patients dilated cardiomyopathy was diagnosed as the underlying disease. One patient with aborted sudden cardiac death had no detectable organic heart disease. The mean age was 59 ±12 years; the mean weight was 75 ±13 kg. The average ejection fraction was 37 ± 14%. There were no significant differences between the patients selected for general (group 1) or local anaesthesia (group 2) as far as clinical data are concerned. In patients with ischaemic heart disease antiplatelet therapy was not suspended prior to device implantation. ) the device and the electrodes were removed as a result of infection. After 10 days of antibiotic treatment, the device was resterilized and reimplanted in the right subpectoral region. Two patients, one of whom had been included in the CAT trial (German cardiomyopathy trial) received a CPI PRx Ill-device (CPI, Inc., St. Paul, MN, U.S.A.) (model 1720, 99 cm 3 , 180g) with an 0115 Endotak C lead.
Devices used
Anaesthesia
In 29 patients (Table 1) operated on between June 1994 and April 1995, surgery was performed under general anaesthesia (isoflurane 0-4-0-6%). In 18 patients (Table  1) operated on from April 1995 to August 1995, surgery was performed under sedation with midazolam (0-9 ± 0-5 mg . kg" 1 i.v.) and local anaesthesia (mepivacaine 1%, 35-40 ml subcutaneously). For the short period of induction of ventricular fibrillation and shock application the patients were additionally sedated with propofol, (0-5 ±01 mg.kg"' i.v.). In order to avoid local pain during injection of this substance, 10 mg lignocaine was applied intravenously immediately before administration of propofol. For haemodynamic monitoring, an arterial cannula was inserted in the right radial artery.
Implantation technique
A small 3 cm long incision was made at the sulcus deltoideopectoralis. The endocardial leads were introduced via venotomy of the cephalic vein in 25 of the 47 patients. In 17 patients the endocardial leads were inserted via puncture of the left subclavian vein. Both venous approaches were used (two-lead devices) in five patients. Depending on the type of lead used, a J-wire was introduced to guide 12F, 14F or 9F split sheaths, used to advance the right ventricular to superior vena cava leads (under posterior-anterior fluoroscopy). The distribution of access between the groups was not significant.
For the defibrillator pocket, a second transverse incision (5-6 cm) at the third intercostal space was made. The pectoralis major and minor muscle were divided along their fibres and the device was placed behind both muscles; starting with the fifth patient the devices were actively fixated at the fascia of the intercostal muscles. The pacing/defibrillator electrodes were tunnelled subcutaneously from the sulcus deltoideopectoralis to the device and connected. The sensing and pacing threshold as well as slew rate and pacing impedance were evaluated. To demonstrate system integrity, an R-wave triggered 05 J test shock was applied by an external test device. Ventricular fibrillation was induced via a T-wave shock; a 24 J biphasic shock was applied. If defibrillation was successful, 6 J decrements were chosen and fibrillation reinduced. If internal defibrillation was not successful, an external 360 J defibrillation shock was applied. Two consecutive successful shocks of 24 J or below were required to implant the system.
Before definite implant of the system, the leads and the connectors were rinsed with hydrogen peroxide (3%), and cephalosporine (2 g Cefotiam) was administered intravenously. After placement of the defibrillator in the retropectoral space and before closure of the wounds, ventricular fibrillation was reinduced and terminated by a 24 J shock by the implanted device. Subcutaneous sutures were applied for wound closure in combination with self adhesive strips. The patients under general anaesthesia were extubated immediately afterwards and transferred to monitored beds for 4 h in an intermediate care unit and thereafter to the cardiology ward. The 18 patients under local anaesthesia were immediately transferred to a cardiology ward with monitoring facilities. Cephalosporine was administered for 2 days (three times 2 g cefotiam) during the postoperative course.
Follow-up procedures
All patients were followed up after 3 to 7 days with defibrillation tests for prehospital discharge. After 4 weeks and every 3 months, patients were evaluated by electrocardiogram, chest X-ray and device check, including interrogation, charge time, pacing threshold, and impedance measurement. 
Statistical methods
Results
In all 47 patients, the non-thoracotomy device was implanted in the subpectoral region. There was no perior postoperative mortality. Ventricular fibrillation could be induced and terminated with defibrillation impulses equal to or below 24 J in all patients; thus, no additional subcutaneous patch electrode was required. Nine patients received a 7219 D Medtronic PCD device with insertion of a right ventricular and a superior vena cava lead. In 29 patients, a 7219 C and in six patients, a 7220 C single lead 'active can' device was implanted (Fig. 1) . In two patients a CPI PRX III system with an Endotak lead was used. All devices delivered biphasic shocks.
The mean operation time was 99 ± 29 min. There was a significant difference in operation time between general and local anaesthesia (107 ±31 min vs 86 ± 20 min; P-Q-Q21). In patients with a two lead configuration, the operation time was considerably longer compared to single lead devices (132 ±36 min vs 97 ±27 min, / > =0021). In 45 patients, the transvenous lead was introduced from the left side. One patient, initially not operated on at our institution, had an abdominal pocket infection and a 'migrating' lead infection up to the left subclavian vein; his whole system had to be removed (PCD 7217 B). This device was reimplanted 10 days later in the right pectoral region with insertion of new endocardial leads through the right subclavian vein.
The mean programmed interval for detection of ventricular fibrillation was 310 ± 16 ms; the mean interval for detection of ventricular tachycardia was 375 ± 53 ms. The defibrillation energy was programmed to the maximum of 34 J for four (7219 C and D), five (PRX III) or six (7220 C) available shocks. In 27 patients, a pacing algorithm for antitachycardia pacing, that began with pacing intervals of usually 81% measured from the ventricular tachycardia cycle length, was chosen. In 10 patients, a stability criterion of less than 50 ms variability of the tachycardia cycle length was programmed to avoid inappropriate device activation' 91 due to known intermittent atrial fibrillation. The mean postoperative stay in hospital was 4-5 ±21 days.
Follow-up
The mean follow-up time was 111 ±4-6 months. In 12 patients, antitachycardia pacing occurred with a mean of 17 ± 16 episodes; in seven patients, a cardioversion or defibrillating impulse was recorded from the stored data with a mean of 6 ± 6 episodes. One patient died of congestive heart failure; the system was inactivated in the terminal stage of the disease. Three patients had a total of 12 inappropriate shocks due to detection of intermittent tachyarrhythmic events during newly developed atrial fibrillation; one of these patients had newly diagnosed hyperthyroidism after iodine exposure.
Complications
There were no major complications. In one patient, an erroneous shock was delivered immediately after the operation in conjunction with left arm movement. This was confirmed by telemetry of intracardiac signals showing high frequency signals which erroneously were interpreted as ventricular fibrillation. The problem was solved by refixation of the set screw connecting the right ventricular and anodal pacing and sensing electrode with the generator. Three patients developed minor local haematoma. One patient temporarily complained of left shoulder pain with impairment of left arm movement. In one patient a minor pneumothorax occurred after device implantation; there was no further intervention necessary. In one patient with a ventricular screw-in lead, a rise in pacing threshold (>8-4V at l-6ms pulse duration) and loss of sensing was detected 10 days after implant. The measured intracardiac signal was 2 mV compared to 18 mV intra-operatively. Upon revision of the endocardial lead a pocket seroma was found, and the whole system was removed. A pocket infection was ruled out by several sterile probes. The generator was resterilized and 10 days later reimplanted together with a steroid eluting tined ventricular electrode (Medtronic Transvene 6934 S) that exhibited no rise in threshold in the follow-up period.
Before we decided to actively fixate the generator, device migration occurred in one patient several weeks after implantation; no therapeutic intervention was required.
Discussion
The present study shows that implantation of internal cardioverter/defibrillators can be safely performed under local anaesthesia and mild sedation solely by electrophysiologists experienced in positioning endocardial leads and in pacemaker implantation techniques. All devices could be placed in the subpectoral region; an additional subcutaneous patch electrode was unnecessary. There was no intra-operative or postoperative mortality and no major complications in our series.
There are only three recently published reports' 10 " 121 concerning defibrillator implants by electrophysiologists. In one series of 23 patients, five complications occurred. In the second report of 100 cardioverter/defibrillators implants by electrophysiologists, acute complications occurred in 10 patients. Furthermore, there were four unsuccessful implant attempts due to failing venous access, elevated defibrillation thresholds, etc. The rate of complication in our patients compares fairly well with these data. Of note, in previous studies bigger devices were implanted with tunnelled leads to an abdominal pocket. In the majority of cases a subcutaneous patch electrode was located; thus the operation time was considerably longer compared to our study (159 ± 45 and 189 ± 5 vs 99 ± 29 min).
Importantly, mortality and infections were not an issue in either series. Compared to previous published peri-operative mortality rates from 2% up to 10% with epicardial implants'
131
, mortality with non-thoracotomy implants is much lower. In data from the PCD Investigator group 1141 , which included 1221 patients, there was a 30-day peri-operative mortality rate of 0-8% for endocardial implants and 4-2% for epicardial systems. In the largest reported series of 110 subpectoral implants (published in abstract form), peri-operative mortality was 14°/<P^.
In contrast to experiences of other investigators published in abstract form'
151
, who used a single incision technique for transvenous subpectoral implants, we preferred a second transverse incision along the third intercostal space for the defibrillator pocket. In our view this approach is advantageous because possible hazards of vessel or nerve lesions' 161 in the axillary region can be avoided. Independent of pocket preparation, the high percentage of successful insertions of defibrillation leads via the cephalic vein is remarkable considering the size of the leads (9F or 14F). Whenever possible, the cephalic approach should be used to avoid complications of subclavian venous puncture and to avoid possible later lead damage via the subclavian approach.
Since small pulse generators with single lead configuration have been available and technical improvements will allow a further downsizing of the device 117>IS1 , implantation techniques should be easier. The subpectoral approach seems in many ways similar to implantation of a VVI pacemaker, but there are important differences. First, an electrophysiological baseline study should be performed to discriminate between broad complex tachycardias and to exclude concomitant supraventricular arrhythmias which might inappropriately activate cardioverter or defibrillator functions'
91
. Secondly, the induction of ventricular fibrillation in patients with impaired left ventricular function under the negative inotropic effects of general anaesthesia is not without risk. There are several reports about difficult termination of ventricular fibrillation in this setting. Furthermore, one publication' 121 showed a 4% complication rate directly related to general anaesthesia in internal cardioverter/defibrillator implantation.
Implantation procedure under local anaesthesia is desirable, and should avoid the above risks. Until now, experience with defibrillator implants under local anaesthesia has been limited. Two recently published studies describe internal cardioverter/defibrillator implantation without general anaesthesia but with defibrillation threshold testing under mild sedation. In one series of 27 patients, 23 received an abdominal two-lead device 1121 ; in four patients a subpectoral two-lead system was implanted. For local anaesthesia 1% lignocaine was used, for analgesia and sedation fentanyl and midazolam was applied intravenously (2-62 ± 100 ug . kg" ' and 207 ± 74 |ig . kg" '). A second study of 12 patients with a single lead unipolar cardioverter/defibrillator has been published recently in abstract form. The implantation was performed under local anaesthesia. Only for defibrillation threshold testing were patients deeply sedated with midazolam (140 ± 50 ug . kg" ') intravenously 1191 . The experience in both reports compare fairly well with our data. In contrast to both studies, we preferred mild sedation with midazolam (93 ± 53ug.kg~') for implantation procedure and deep sedation with propofol (0-46 ±013 mg . kg" ') for induction and termination of ventricular fibrillation. Compared to midazolam, propofol has no analgesic effect but an excellent hypnotic effect, a very short half-life, less postoperative sedation, drowsiness, confusion, clumsiness, and amnesia, as well as more rapid recovery of cognitive functions' . The well described cardiodepressive effect and hypotension under propofol occurs in 10 times higher doses than used in our study* 22 '. Despite the fact that this is a non-randomized study, there were no significant differences between the groups, except for operation times. However, our mean operation time (skin to skin: 99 ± 29 min) compares well with other authors' 9 ' 101 . The operation time under local anaesthesia was significantly shorter than in general anaesthesia, but because of the limited database and the non-randomized nature of our study this result should be interpreted with caution. It may well represent the learning effect which has a significant impact on implant duration' 23 '.
Limitations
This is a non-randomized study. Originally, we intended to randomize patients to either form of anaesthesia. However, having implanted the first devices under local anaesthesia it was our general feeling that this method was much better tolerated as far as postoperative recovery, cardiocirculatory parameters, and patient acceptance were concerned. Until now there has been no standard procedure concerning submuscular/subcutaneous or single/double incision implantation techniques for the available devices. No doubt, with even smaller devices a single incision technique with a subcutaneous pocket under local anaesthesia will be the method of choice. In our view, it is advantageous if electrophysiologists place the endocardial leads; however, pocket preparation could be carried out by a surgeon, as is common practice in many pacemaker implants. In our opinion each centre should perform more than 12 implants per year, a number suggested by Parsonnet' 24 ' for pacemaker implants' 24 '. In this way, intra-operative and peri-operative complications can be reduced.
